SylvanLabs
Executive Summary
Neurodegenrative and inflammatory disorders
You may also be interested in...
CureVac Launches IPO, Adds To Big 2020 Cash Haul
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.
US FDA Finds Four More Firms Selling Unapproved COVID-19 Tests OTC, Including Stool Sample Kit
One stool sample kit and three serology tests are identified in the agency’s latest warning on OTC sales of unapproved COVID-19 tests. One of the warned firm continues offering sales of its violative product.
Orthopedic Device Firms Lobby Hard On COVID-19 Relief And Reimbursements, Among Other Issues
Firms including Depuy Synthes, Medtronic Inc., and Zimmer Biomet Holdings Inc., spent thousands of dollars lobbying Congress last winter.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports